Figure 3 . HA-specific IgG1, IgG2a and Omicron BA.5
S-RBD-specific IgG1, IgG2a detection in immunized mouse sera.
HA-specific
IgG1(A) and
IgG2a(C) endpoint titers on day 21 and day 35 in
immunized mouse sera; Omicron BA.5 S-RBD-specific
IgG1(B) and IgG2a(D) endpoint titers on
day 21 and day 35 in immunized mouse sera. Statistical significance was
determined by two-way ANOVA and is indicated as follows: * p< 0.05, ** p < 0.01, *** p <
0.001, **** p < 0.0001. Error bars represent SD.
3.3Influenza/SARS-CoV-2
Omicron Subunit Combined Vaccine Induced High Levels of H1N1
A/California/07/2009 Virus-specific Hemagglutination-inhibiting
Antibodies in Mice
The H1N1 A/California/07/2009 virus-specific hemagglutination-inhibiting
antibody titers in immunized mouse sera on day 21 and 35 were detected
by HAI assay. As shown in Figure 4, a quite high level of H1N1
A/California/07/2009 virus-specific HAI titer was detected in mice
immunized with HA with no significant difference between the HA and
HA+SARS-CoV-2 Omicron BA.5 S immunized groups. HAI titer was
significantly increased on day 35 in mice immunized with HA, again with
no significant difference between the HA and HA+SARS-CoV-2 Omicron BA.5
S immunized groups.